Verseau Therapeutics that develops novel, first-in-class immunotherapies on Monday announced the completion of a $50-million new round of financing.
Hong Kong-listed biotech firm 3SBio, Shanghai-based investment company Highlight Capital, and Chinese private equity firm Yonghua Capital invested in the new round, according to a company statement.
